vs
Inotiv, Inc.（NOTV）与NATIONAL RESEARCH CORP（NRC）财务数据对比。点击上方公司名可切换其他公司
Inotiv, Inc.的季度营收约是NATIONAL RESEARCH CORP的3.4倍（$120.9M vs $35.2M）。NATIONAL RESEARCH CORP净利率更高（5.1% vs -23.5%，领先28.6%）。Inotiv, Inc.同比增速更快（0.8% vs -4.6%）。NATIONAL RESEARCH CORP自由现金流更多（$6.1M vs $-10.6M）。过去两年Inotiv, Inc.的营收复合增速更高（0.8% vs -0.2%）
Inotiv公司是一家注册于美国印第安纳州的合同研究组织，总部位于该州拉斐特市。公司设有两大核心业务板块：发现与安全评估业务（DSA）以及研究模型与服务业务（RMS），可为小分子候选药物、生物治疗产品及生物医疗设备提供安全评估、分析、代谢研究、CMC及法规咨询等药物开发与环境科学相关服务。
NRC Health（原国家研究公司）是一家美国医疗健康企业，1981年成立，总部位于内布拉斯加州林肯市。公司主要在美加两国提供医疗健康相关产品及订阅式解决方案，深耕区域医疗健康服务领域。
NOTV vs NRC — 直观对比
营收规模更大
NOTV
是对方的3.4倍
$35.2M
营收增速更快
NOTV
高出5.5%
-4.6%
净利率更高
NRC
高出28.6%
-23.5%
自由现金流更多
NRC
多$16.7M
$-10.6M
两年增速更快
NOTV
近两年复合增速
-0.2%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $120.9M | $35.2M |
| 净利润 | $-28.4M | $1.8M |
| 毛利率 | — | — |
| 营业利润率 | -13.5% | 13.3% |
| 净利率 | -23.5% | 5.1% |
| 营收同比 | 0.8% | -4.6% |
| 净利润同比 | -2.7% | -72.6% |
| 每股收益（稀释后） | $-0.83 | $49.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NOTVNRC
| Q4 25 | $120.9M | $35.2M | ||
| Q3 25 | $138.1M | $34.6M | ||
| Q2 25 | $130.7M | $34.0M | ||
| Q1 25 | $124.3M | $33.6M | ||
| Q4 24 | $119.9M | $36.9M | ||
| Q3 24 | $130.4M | $35.8M | ||
| Q2 24 | $105.8M | $35.0M | ||
| Q1 24 | $119.0M | $35.3M |
净利润NOTVNRC
| Q4 25 | $-28.4M | $1.8M | ||
| Q3 25 | $-8.6M | $4.1M | ||
| Q2 25 | $-17.6M | $-106.0K | ||
| Q1 25 | $-14.9M | $5.8M | ||
| Q4 24 | $-27.6M | $6.6M | ||
| Q3 24 | $-18.9M | $5.7M | ||
| Q2 24 | $-26.1M | $6.2M | ||
| Q1 24 | $-48.1M | $6.4M |
营业利润率NOTVNRC
| Q4 25 | -13.5% | 13.3% | ||
| Q3 25 | -4.9% | 22.4% | ||
| Q2 25 | -4.3% | 4.7% | ||
| Q1 25 | -2.4% | 25.6% | ||
| Q4 24 | -12.9% | 26.0% | ||
| Q3 24 | -10.1% | 22.3% | ||
| Q2 24 | -19.6% | 25.3% | ||
| Q1 24 | -36.2% | 24.8% |
净利率NOTVNRC
| Q4 25 | -23.5% | 5.1% | ||
| Q3 25 | -6.2% | 11.9% | ||
| Q2 25 | -13.5% | -0.3% | ||
| Q1 25 | -12.0% | 17.2% | ||
| Q4 24 | -23.0% | 17.8% | ||
| Q3 24 | -14.5% | 15.9% | ||
| Q2 24 | -24.7% | 17.6% | ||
| Q1 24 | -40.4% | 18.0% |
每股收益（稀释后）NOTVNRC
| Q4 25 | $-0.83 | $49.58 | ||
| Q3 25 | $-0.14 | $0.18 | ||
| Q2 25 | $-0.51 | $-0.01 | ||
| Q1 25 | $-0.44 | $0.25 | ||
| Q4 24 | $-1.02 | $0.27 | ||
| Q3 24 | $-0.73 | $0.24 | ||
| Q2 24 | $-1.00 | $0.26 | ||
| Q1 24 | $-1.86 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.7M | $4.1M |
| 总债务越低越好 | $405.8M | — |
| 股东权益账面价值 | $109.0M | $14.0M |
| 总资产 | $734.3M | $134.9M |
| 负债/权益比越低杠杆越低 | 3.72× | — |
8季度趋势，按日历期对齐
现金及短期投资NOTVNRC
| Q4 25 | $12.7M | $4.1M | ||
| Q3 25 | $21.7M | $2.2M | ||
| Q2 25 | $6.2M | $5.3M | ||
| Q1 25 | $19.3M | $2.5M | ||
| Q4 24 | $38.0M | $4.2M | ||
| Q3 24 | $21.4M | $3.5M | ||
| Q2 24 | $14.4M | $485.0K | ||
| Q1 24 | $32.7M | $1.7M |
总债务NOTVNRC
| Q4 25 | $405.8M | — | ||
| Q3 25 | $402.1M | — | ||
| Q2 25 | $396.5M | — | ||
| Q1 25 | $399.5M | — | ||
| Q4 24 | $396.0M | — | ||
| Q3 24 | $393.3M | $48.7M | ||
| Q2 24 | $382.4M | $33.3M | ||
| Q1 24 | $380.6M | $35.2M |
股东权益NOTVNRC
| Q4 25 | $109.0M | $14.0M | ||
| Q3 25 | $136.0M | $14.3M | ||
| Q2 25 | $143.8M | $21.3M | ||
| Q1 25 | $157.7M | $29.7M | ||
| Q4 24 | $169.8M | $31.3M | ||
| Q3 24 | $170.5M | $34.6M | ||
| Q2 24 | $182.1M | $40.2M | ||
| Q1 24 | $207.2M | $36.9M |
总资产NOTVNRC
| Q4 25 | $734.3M | $134.9M | ||
| Q3 25 | $771.1M | $135.7M | ||
| Q2 25 | $759.7M | $141.4M | ||
| Q1 25 | $766.0M | $135.2M | ||
| Q4 24 | $772.9M | $132.5M | ||
| Q3 24 | $781.4M | $131.8M | ||
| Q2 24 | $774.6M | $119.1M | ||
| Q1 24 | $815.4M | $120.9M |
负债/权益比NOTVNRC
| Q4 25 | 3.72× | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | 2.76× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.33× | — | ||
| Q3 24 | 2.31× | 1.41× | ||
| Q2 24 | 2.10× | 0.83× | ||
| Q1 24 | 1.84× | 0.95× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.4M | $7.2M |
| 自由现金流经营现金流 - 资本支出 | $-10.6M | $6.1M |
| 自由现金流率自由现金流/营收 | -8.8% | 17.2% |
| 资本支出强度资本支出/营收 | 4.3% | 3.2% |
| 现金转化率经营现金流/净利润 | — | 3.99× |
| 过去12个月自由现金流最近4个季度 | $-28.7M | $15.7M |
8季度趋势，按日历期对齐
经营现金流NOTVNRC
| Q4 25 | $-5.4M | $7.2M | ||
| Q3 25 | $14.3M | $13.8M | ||
| Q2 25 | $-7.4M | $-1.1M | ||
| Q1 25 | $-12.8M | $6.6M | ||
| Q4 24 | $-4.5M | $6.4M | ||
| Q3 24 | $-2.4M | $9.4M | ||
| Q2 24 | $-14.8M | $6.8M | ||
| Q1 24 | $16.9M | $12.0M |
自由现金流NOTVNRC
| Q4 25 | $-10.6M | $6.1M | ||
| Q3 25 | $11.6M | $10.2M | ||
| Q2 25 | $-11.5M | $-4.1M | ||
| Q1 25 | $-18.3M | $3.7M | ||
| Q4 24 | $-9.0M | $1.9M | ||
| Q3 24 | $-7.7M | $7.8M | ||
| Q2 24 | $-19.2M | $1.5M | ||
| Q1 24 | $9.9M | $7.9M |
自由现金流率NOTVNRC
| Q4 25 | -8.8% | 17.2% | ||
| Q3 25 | 8.4% | 29.4% | ||
| Q2 25 | -8.8% | -12.2% | ||
| Q1 25 | -14.7% | 10.9% | ||
| Q4 24 | -7.5% | 5.2% | ||
| Q3 24 | -5.9% | 21.8% | ||
| Q2 24 | -18.2% | 4.3% | ||
| Q1 24 | 8.3% | 22.4% |
资本支出强度NOTVNRC
| Q4 25 | 4.3% | 3.2% | ||
| Q3 25 | 1.9% | 10.4% | ||
| Q2 25 | 3.1% | 8.8% | ||
| Q1 25 | 4.4% | 8.9% | ||
| Q4 24 | 3.7% | 12.0% | ||
| Q3 24 | 4.1% | 4.5% | ||
| Q2 24 | 4.2% | 15.0% | ||
| Q1 24 | 5.9% | 11.7% |
现金转化率NOTVNRC
| Q4 25 | — | 3.99× | ||
| Q3 25 | — | 3.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NOTV
| Research Models And Services Segment | $72.9M | 60% |
| Discovery And Safety Assessment Segment | $48.0M | 40% |
NRC
暂无分部数据
